Navigation Links
Pharma majors gear to supply anti-anthrax drug

The panic that has gripped the U.S with anthrax bacterial infections coming to light has led to an increased demand for the drug used in its treatment - Ciprofloxacin. Already there is news that the German pharma major Bayer is tripling its production of Ciprofloxacin to cater to the burgeoning demand and will supply 200 million tablets in the next three months. In fact, Bayer holds the U.S. patents on the most common forms of Ciprofloxacin and these expire on December 9, 2003. //

Ranbaxy Laboratories produces both the bulk and formulation forms of ciprofloxacin and according to a company spokesman, the U.S. Senator, Mr. Charles Schumer, has approached Ranbaxy's U.S. arm, Ranbaxy Laboratories Inc. regarding supply of Cipro in large numbers - Mr. Schumer had asked Ranbaxy for a supply of 20 million tablets a month of Ciprofloxacin for anthrax treatment starting December. The treatment for anthrax entails one ciprofloxacin twice a day and the U.S. Government wants to purchase enough Ciprofloxacin to cover 12 million patients for 60 days.

Ranbaxy is among the few Indian companies with the U.S. Food and Drug Administration(FDA) approval for the manufacture of Ciprofloxacin. The Mumbai-based Cipla, which is also approved by the U.S. FDA, has also offered to supply large quantities of Ciprofloxacin, the active ingredient of Cipro to a generic producer in the U.S.

Ciprofloxacin is a U.S. FDA wide spectrum antibiotic for the treatment of anthrax and belongs to the fluoroquinolone class of drugs which has a global market of $3.85 billion and is reportedly growing at 16 percent per annum. In India, Ciprofloxacin is the second largest molecule after Amoxycillin.


'"/>




Page: 1

Related medicine news :

1. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Pharma cos must forge Strategic alliances
4. Medicis Pharmaceutical company enters pediatric market
5. Pharmacies in for a dose of bitter medicine
6. Andhra Pradesh to set up Pharma City
7. Sun Pharma to launch chiral version of omeprazole soon
8. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
9. Pharmacia may take 51.5 percent Abbott stake
10. Pharmaceutical companies are targeting patients
11. FDA approves Watson Pharmaceuticals Oxytrol patch
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2017)... ... 2017 , ... International Protein, a company based out of Australia that focuses ... January ECRM trade show in Hilton Head, SC. , International Protein was founded ... a line of products that would elevate her fitness regime. At this ECRM trade ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... sugar-free alternative VW+ 002. The drinks have been produced in collaboration with Zlatan ... perform during your workout. , After a successful launch in Sweden last year, ...
(Date:1/20/2017)... ... 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a man who went ... creation of published author, Marlyn Ivey, born in Lynn Haven, Florida and at the age ... at 19 years of age, he joined the Navy and got married right out of ...
(Date:1/20/2017)... ... ... in Suffolk”: a story of love, secrets, and mystery. “Christmas in Suffolk” is ... works in a daycare and looks for inspiration in the local coffee shop as ... Seymour’s new book is an adventure of love and secrets. , After ...
(Date:1/20/2017)... ... ... “The Land of More and More”: a brilliant story for children and adults ... and achievable answer. “The Land of More and More” is the creation of published ... Indiana where he works with the children’s ministry department. , Michael says that ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 ViewRay, Inc. ... a federal institution supporting research in Germany ... and patient treatments at the University Clinic Heidelberg as ... The MRIdian Linac program will be headed by ... also heads radiation oncology at the German Cancer Research ...
(Date:1/19/2017)... 19, 2017   Science Exchange , the leading ... that the first five replication studies from the ... published in eLife today. Despite intense scrutiny around ... practical evaluation of reproducibility rates that may identify ... other assessments of reproducibility, the results of this ...
(Date:1/19/2017)... , January 19, 2017 ... Option to Address Motor Symptoms and Motor Complications ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) ... , European Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late ...
Breaking Medicine Technology: